Literature DB >> 28941781

Glucocorticoids and Toll-like receptor 2 cooperatively induce acute-phase serum amyloid A.

Qi Su1, Günther Weindl2.   

Abstract

Serum amyloid A (SAA) is a highly conserved acute-phase protein and extrahepatic produced SAA1/2 contributes to cutaneous inflammation. Prolonged systemic or topical treatment with glucocorticoids can provoke skin diseases such as steroid-induced acne. Glucocorticoids increase Toll-like receptor 2 (TLR2) expression, however, an inflammatory mediator linked to this side effect remains elusive. We report that TLR2 agonists in combination with dexamethasone substantially increase SAA expression and production in human keratinocytes and epithelial cells. Dexamethasone-mediated SAA1 induction depends on the glucocorticoid receptor (GR). In response to Propionibacterium acnes, TLR2-activated signal transducer and activator of transcription 3 (STAT3) and nuclear factor κB (NF-κB) signaling pathways are critically involved in dexamethasone-induced SAA1 production. The formation of transcription factor complexes between GR or p300 and phospho-STAT3 was confirmed by co-immunoprecipitation in dexamethasone- and P. acnes-stimulated keratinocytes. Furthermore, dexamethasone and P. acnes-increased TLR2 and mitogen-activated protein kinase phosphatase-1 (MKP-1) contribute to induction of SAA1 and 2. Likewise, tumor necrosis factor (TNF) induces SAA1 in combination with dexamethasone. GR, transcription factors STAT3 and NF-κB, but not MKP-1, mediate TNF- and dexamethasone-induced SAA1. Conclusively, we provide evidence that glucocorticoids promote SAA1 production under infectious and sterile inflammatory conditions which may provide significant insights to the pathogenesis of steroid-induced acne.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Glucocorticoids; Serum amyloid A; Skin; Toll-like receptor 2; Transcription factors

Mesh:

Substances:

Year:  2017        PMID: 28941781     DOI: 10.1016/j.phrs.2017.09.012

Source DB:  PubMed          Journal:  Pharmacol Res        ISSN: 1043-6618            Impact factor:   7.658


  5 in total

1.  Responsiveness to Parenteral Corticosteroids and Lung Function Trajectory in Adults with Moderate-to-Severe Asthma.

Authors:  Loren C Denlinger; Brenda R Phillips; Ronald L Sorkness; Eugene R Bleecker; Mario Castro; Mark D DeBoer; Anne M Fitzpatrick; Annette T Hastie; Jonathan M Gaffin; Wendy C Moore; Michael C Peters; Stephen P Peters; Wanda Phipatanakul; Juan Carlos Cardet; Serpil C Erzurum; John V Fahy; Merritt L Fajt; Benjamin Gaston; Bruce D Levy; Deborah A Meyers; Kristie Ross; W Gerald Teague; Sally E Wenzel; Prescott G Woodruff; Joe Zein; Nizar N Jarjour; David T Mauger; Elliot Israel
Journal:  Am J Respir Crit Care Med       Date:  2021-04-01       Impact factor: 21.405

2.  Genome wide analysis of TLR1/2- and TLR4-activated SZ95 sebocytes reveals a complex immune-competence and identifies serum amyloid A as a marker for activated sebaceous glands.

Authors:  Dániel Törőcsik; Dóra Kovács; Szilárd Póliska; Zita Szentkereszty-Kovács; Marianna Lovászi; Katalin Hegyi; Andrea Szegedi; Christos C Zouboulis; Mona Ståhle
Journal:  PLoS One       Date:  2018-06-21       Impact factor: 3.240

Review 3.  The Association of Acute Phase Proteins in Stress and Inflammation-Induced T2D.

Authors:  Tammy Speelman; Lieke Dale; Ann Louw; Nicolette J D Verhoog
Journal:  Cells       Date:  2022-07-11       Impact factor: 7.666

4.  Naturally occurring antibodies against serum amyloid A reduce IL-6 release from peripheral blood mononuclear cells.

Authors:  Tadeja Kuret; Katja Lakota; Polonca Mali; Saša Čučnik; Sonja Praprotnik; Matija Tomšič; Snezna Sodin-Semrl
Journal:  PLoS One       Date:  2018-04-04       Impact factor: 3.240

5.  Biological Characterization, Mechanistic Investigation and Structure-Activity Relationships of Chemically Stable TLR2 Antagonists.

Authors:  Marcel Bermudez; Maria Grabowski; Manuela S Murgueitio; Markus Tiemann; Péter Varga; Thomas Rudolf; Gerhard Wolber; Günther Weindl; Jörg Rademann
Journal:  ChemMedChem       Date:  2020-06-03       Impact factor: 3.466

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.